All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Group and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 31% of the shareholders present or…
Biophytis Joins Silver Innov’, an Incubator Dedicated to the Silver Economy Biophytis is relocating to Silver Innov, an incubator and business center specialized in innovation, healthcare, and aging. This move represents a key milestone in Biophytis’ strategic roadmap, reinforcing its presence within an ecosystem dedicated to the silver economy, healthy aging, and biopharmaceutical innovation. As…
RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with…
Combined General Meeting of June 24, 2024 Biophytis will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université – Amphi Herpin – 4 Place Jussieu, 75005 Paris. The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des…
RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a…
Combined General Meeting of April 2, 2024 Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, will hold…
“Live healthier longer” – Publication of a book on the medicine and science of longevity Biophytis announces the publication of a book written by Stanislas Veillet, CEO and co- founder of the company, together with René Lafont, Professor Emeritus at Sorbonne University and co- founder of Biophytis, and Jean Mariani, Professor and Director of the…
Results of the annual general meeting on june 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED Biophytis announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting. Thanks to the mobilization of shareholders, the AGM could be…
The Combined General Meeting will be held on second call on April 17, 2023 Fullscreen Mode
Biophytis announced it is convening an Extraordinary and Ordinary Shareholders’ Meeting for March 30, 2023 Delegation to the Board of Directors to reduce the nominal value Regrouping of the company’s shares Renewal of Authorizations granted at the June 2022 AGM Stanislas Veillet, CEO of Biophytis, stated: “Following COVA study positive results, we now wishe to…
Judgment of the Paris Court of Appeal of 17 January 2023 in the case between Biophytis and Negma Group Ltd The Paris Court of appeal confirms the judgement of the Paris Conmmercial Court of 16th of March 2021 Fullscreen Mode
Biophytis announces that on the 8th of September 2022 the Paris Court of Appeal rendered a decision in the case between Biophytis and Negma Group Ltd.
Results of the Combined General Meeting on June 21, 2022 All ordinary and extraordinary resolutions presented by the company have been adopted Biophytis announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting. Thanks to the mobilization of shareholders, the…
Convening of Another Combined General Meeting at a Later Date Biophytis informs its shareholders that the combined Annual General Meeting (AGM) held on June 3, 2022 was unable to deliberate, as the required quorum was not reached. The shareholders taking part in the vote owned collectively 23 514 980 shares, or 15.45% of the share…
Results of the Combined General Meeting on May 10, 2021
Biophytis - Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
Biophytis - Convening of Another Combined General Meeting at a Later Date
Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021
Biophytis Identifies False Report Regarding COVA Study
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd
Biophytis AGM meeting will take place on April 26, 2021
Paris Court of Appeal rules in Biophytis’ favor in connection with the dispute with NEGMA. Read the Press Release
Results of the Combined General Meeting of May 28, 2020: All ordinary and extraordinary resolutions have been adopted. Read the Press Release
Biophytis second AGM to take place on May 28, 2020 without the physical presence of its shareholders. Read the Press Release
Convening of another combined General Meeting at a Later Date. Read the Press Release
Biophytis AGM meeting will take place on May 11, 2020 without the physical presence of its shareholders. Read the Press Release
Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS. Read the Press Release
